Pharmacoepigenomics in colorectal cancer: A step forward in predicting prognosis and treatment response

Pharmacogenomics

Volumn 9, Issue 12, 2008, Pages 1903-1916

  Smits, Kim M ^a   Cleven, Arjen H G ^b   Weijenberg, Matty P ^a   Hughes, Laura A E ^a   Herman, James G ^c   De Brune, Adriaan P ^b   Van Engeland, Manon ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

colorectal cancer; epigenetics; pharmacoepigenomics; pharmacogenetics; prognosis; treatment outcome

Indexed keywords

BEVACIZUMAB; CETUXIMAB; DNA; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PROTEIN CHFR; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG; WERNER SYNDROME PROTEIN;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER INCIDENCE; CANCER SURGERY; COLONOSCOPY; COLORECTAL CANCER; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENETIC MARKER; HUMAN; LIFESTYLE; PHARMACOGENOMICS; PHENOTYPE; PREDICTION; PROGNOSIS; REVIEW; STOMACH CANCER; TREATMENT RESPONSE; TUMOR GENE; COLORECTAL TUMOR; GENETIC EPIGENESIS; GENETICS; PHARMACOGENETICS; TREATMENT OUTCOME;

COLORECTAL NEOPLASMS; EPIGENESIS, GENETIC; GENETIC MARKERS; HUMANS; PHARMACOGENETICS; PROGNOSIS; TREATMENT OUTCOME;

EID: 61549091202     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.12.1903     Document Type: Review

References (134)

1. Klump B, Nehls O, Okech T et al.: Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature. Int. J. Colorectal Dis. 19(1), 23-42 (2004). (Pubitemid 38088282)
2. Graziano F, Cascinu S: Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes B colorectal cancer patients: how much evidence is enough? Ann. Oncol. 14(7), 1026-1038 (2003). (Pubitemid 36950166)
3. McLeod HL, Murray GI: Tumour markers of prognosis in colorectal cancer. Br. J. Cancer 79(2), 191-203 (1999). (Pubitemid 29002285)
4. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18(3), 581-592 (2007). (Pubitemid 46359643)
5. GLOBOCAN I: Cancer Incidence Mortality and Prevalence Worldwide. 2002.
6. WCRF, AICR: Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington DC: AICR, 2007.
7. Mariotto AB, Rowland JH, Ries LA, Scoppa S, Feuer EJ: Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol. Biomarkers Prev. 16(3), 566-571 (2007). (Pubitemid 46548662)
8. Seeff LC, Richards TB, Shapiro JA et al.: How many endoscopies are performed for colorectal cancer screening? Results from CDCs survey of endoscopic capacity. Gastroenterology 127(6), 1670-1677 (2004).
9. Bressler B, Lo C, Amar J et al.: Prospective evaluation of screening colonoscopy: who is being screened? Gastrointest. Endosc. 60(6), 921-926 (2004). (Pubitemid 39655466)
10. Whitney D, Skoletsky J, Moore K et al.: Enhanced retrieval of DNA from human fecal samples results in improved performance of colorectal cancer screening test. J. Mol. Diagn. 6(4), 386-395 (2004). (Pubitemid 39517408)
11. Levin B, Lieberman DA, McFarland B et al.: Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134(5), 1570-1595 (2008). (Pubitemid 351615355)
12. Huang Z, Li L, Wang J: Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig. Dis. Sci. 52(9), 2287-2291 (2007). (Pubitemid 47246528)
13. Wang DR, Tang D: Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J. Gastroenterol. 14(4), 524-531 (2008). (Pubitemid 351320817)
14. Hamilton SR, Aaltonen L (Eds).: Pathology & Genetics of Tumours of the Digestive System. World Health Organization of the Digestive System. Lyon, France: International Agency for Research on Cancer, 2000.
15. Compton CC, Greene FL: The staging of colorectal cancer: 2004 and beyond. CA Cancer J. Clin. 54(6), 295-308 (2004).
16. Vogelstein B, Bearon ER, Hamilton SR: Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319, 525-532 (1988).
17. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61(5), 759-767 (1990). (Pubitemid 20185636)
18. Powell SM, Zilz N, Beazer-Barclay Y et al.: APC mutations occur early during colorectal tumorigenesis. Nature 359(6392), 235-237 (1992).
19. Groden J, Thliveris A, Samowitz W et al.: Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66(3), 589-600 (1991). (Pubitemid 121001394)
20. Tomlinson I, Ilyas M, Novelli M: Molecular genetics of colon cancer. Cancer Metastasis Rev. 16(1-2), 67-79 (1997). (Pubitemid 27219471)
21. Kolligs FT, Bommer G, Goke B: Wnt/β-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis. Digestion 66(3), 131-144 (2002). (Pubitemid 36091845)
22. Janssen KP, Alberici P, Fsihi H et al.: APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology 131(4), 1096-1109 (2006). (Pubitemid 44498698)
23. Fodde R: The APC gene in colorectal cancer. Eur. J. Cancer 38(7), 867-871 (2002). (Pubitemid 34442313)
24. Houlston RS, Tomlinson IP: Genetic prognostic markers in colorectal cancer. Mol. Pathol. 50(6), 281-288 (1997). (Pubitemid 28057236)
25. Miranda E, Destro A, Malesci A et al.: Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer. Br. J. Cancer 95(8), 1101-1107 (2006). (Pubitemid 44606839)
26. Imai K, Yamamoto H: Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 29(4), 673-680 (2008). (Pubitemid 351494153)
27. Fearon ER, Cho KR, Nigro JM et al.: Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247(4938), 49-56 (1990). (Pubitemid 20059936)
28. Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer of the proximal colon. Science 260(5109), 816-819 (1993). (Pubitemid 23167612)
29. Miyakura Y, Sugano K, Konishi F et al.: Methylation profile of the MLH1 promoter region and their relationship to colorectal carcinogenesis. Genes Chromosomes Cancer 36(1), 17-25 (2003). (Pubitemid 36077378)
30. Leslie A, Carey FA, Pratt NR, Steele RJ: The colorectal adenoma-carcinoma sequence. Br. J. Surg. 89(7), 845-860 (2002). (Pubitemid 34779568)
31. Sjoblom T, Jones S, Wood LD et al.: The consensus coding sequences of human breast and colorectal cancers. Science 314(5797), 268-274 (2006). (Pubitemid 44571966)
32. Wood LD, Parsons DW, Jones S et al.: The genomic landscapes of human breast and colorectal cancers. Science 318(5853), 1108-1113 (2007). (Pubitemid 350134889)
33. Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat. Med. 10(8), 789-799 (2004). (Pubitemid 39070849)
34. Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 87(2), 159-170 (1996). (Pubitemid 26358996)
35. Walther A, Houlston R, Tomlinson I: Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut 57(7), 941-950 (2008). (Pubitemid 351919529)
36. Locker GY, Hamilton S, Harris J et al.: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 24(33), 5313-5327 (2006). (Pubitemid 46631379)
37. Castagnola P, Giaretti W: Mutant KRAS, chromosomal instability and prognosis in colorectal cancer. Biochim. Biophys. Acta 1756(2), 115-125 (2005). (Pubitemid 41773138)
38. Anwar S, Frayling IM, Scott NA, Carlson GL: Systematic review of genetic influences on the prognosis of colorectal cancer. Br. J. Surg. 91(10), 1275-1291 (2004). (Pubitemid 39331451)
39. Westra JL, Plukker JT, Buys CH, Hofstra RM: Genetic alterations in locally advanced stage II/III colon cancer: a search for prognostic markers. Clin. Colorectal Cancer 4(4), 252-259 (2004).
40. Samowitz WS, Sweeney C, Herrick J et al.: Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 65(14), 6063-6069 (2005). (Pubitemid 40994390)
41. Lanza G, Matteuzzi M, Gafa R et al.: Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int. J. Cancer 79(4), 390-395 (1998). (Pubitemid 28359738)
42. Jen J, Kim H, Piantadosi S et al.: Allelic loss of chromosome 18q and prognosis in colorectal cancer. N. Engl. J. Med. 331(4), 213-221 (1994). (Pubitemid 24226678)
43. Postma C, Terwischa S, Hermsen MA, van der Sijp JR, Meijer GA: Gain of chromosome 20q is an indicator of poor prognosis in colorectal cancer. Cell Oncol. 29(1), 73-75 (2007). (Pubitemid 46535195)
44. Sinicrope FA, Rego RL, Halling KC et al.: Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 131(3), 729-737 (2006).
45. Ulrich CM, Curtin K, Potter JD, Bigler J, Caan B, Slattery ML: Polymorphisms in the reduced folate carrier, thymidylate synthase, or methionine synthase and risk of colon cancer. Cancer Epidemiol. Biomarkers Prev. 14(11 Pt 1), 2509-2516 (2005). (Pubitemid 41752708)
46. Dotor E, Cuatrecases M, Martinez-Iniesta M et al.: Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J. Clin. Oncol. 24(10), 1603-1611 (2006). (Pubitemid 46638784)
47. Chen J, Hunter DJ, Stampfer MJ et al.: Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 12(10), 958-962 (2003). (Pubitemid 37310249)
48. Curtin K, Ulrich CM, Samowitz WS et al.: Thymidylate synthase polymorphisms and colon cancer: associations with tumor stage, tumor characteristics and survival. Int. J. Cancer 120(10), 2226-2232 (2007). (Pubitemid 46555863)
49. Bacman D, Merkel S, Croner R, Papadopoulos T, Brueckl W, Dimmler A: TGF-β receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-β1 expression in colon carcinoma: a retrospective study. BMC Cancer 7, 156 (2007). (Pubitemid 47487590)
50. Robson H, Anderson E, James RD, Schofield PF: Transforming growth factor β1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. Br. J. Cancer 74(5), 753-758 (1996). (Pubitemid 26300767)
51. Kouraklis G, Kakisis J, Theoharis S et al.: Prognostic significance and correlation with survival of bcl-2 and TGF-β RII in colon cancer. Dig. Dis. Sci. 48(12), 2284-2289 (2003). (Pubitemid 38021732)
52. Spano JP, Milano G, Vignot S, Khayat D: Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer. Crit. Rev. Oncol. Hematol. 66(1), 21-30 (2008).
53. Chan TA, Glockner S, Yi JM et al.: Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med. 5(5), E114 (2008). (Pubitemid 351760910)
54. Herman JG: Hypermethylation of tumor suppressor genes in cancer. Semin. Cancer Biol. 9(5), 359-367 (1999). (Pubitemid 29532862)
55. Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349(21), 2042-2054 (2003). (Pubitemid 37448928)
56. Jones PA, Baylin SB: The epigenomics of cancer. Cell 128(4), 683-692 (2007).
57. Esteller M, Herman JG: Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J. Pathol. 196(1), 1-7 (2002). (Pubitemid 34814766)
58. Schuebel KE, Chen W, Cope L et al.: Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet. 3(9), 1709-1723 (2007). (Pubitemid 47510263)
59. Weisenberger DJ, Siegmund KD, Campan M et al.: CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 38(7), 787-793 (2006). (Pubitemid 43980599)
60. Samowitz WS, Albertsen H, Herrick J et al.: Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 129(3), 837-845 (2005). (Pubitemid 41242676)
61. Ogino S, Odze RD, Kawasaki T et al.: Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Am. J. Surg. Pathol. 30(9), 1175-1183 (2006). (Pubitemid 44299351)
62. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP: CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA 96(15), 8681-8686 (1999). (Pubitemid 29354851)
63. Shen L, Toyota M, Kondo Y et al.: Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl Acad. Sci. USA 104(47), 18654-18659 (2007). (Pubitemid 350210752)
64. Ogino S, Goel A: Molecular classification and correlates in colorectal cancer. J. Mol. Diagn. 10(1), 13-27 (2008). (Pubitemid 351184831)
65. Issa JP: CpG island methylator phenotype in cancer. Nat. Rev. Cancer 4(12), 988-993 (2004).
66. Ogino S, Meyerhardt JA, Kawasaki T et al.: CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 450(5), 529-537 (2007). (Pubitemid 46676250)
67. van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B: CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin. Cancer Res. 9(8), 2898-2903 (2003). (Pubitemid 36993247)
68. Hawkins N, Norrie M, Cheong K et al.: CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 122(5), 1376-1387 (2002). (Pubitemid 34465180)
69. van Rijnsoever M, Grieu F, Elsaleh H, Joseph D, Iacopetta B: Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 51(6), 797-802 (2002). (Pubitemid 35408598)
70. Popat S, Hubner R, Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 23(3), 609-618 (2005). (Pubitemid 46224239)
71. Wright CM, Dent OF, Barker M et al.: Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br. J. Surg. 87(9), 1197-1202 (2000).
72. Gryfe R, Kim H, Hsieh ET et al.: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N. Engl. J. Med. 342(2), 69-77 (2000). (Pubitemid 30036597)
73. Whitehall VL, Walsh MD, Young J, Leggett BA, Jass JR: Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. Cancer Res. 61(3), 827-830 (2001). (Pubitemid 32174386)
74. Kohonen-Corish MR, Daniel JJ, Chan C et al.: Low microsatellite instability is associated with poor prognosis in stage C colon cancer. J. Clin. Oncol. 23(10), 2318-2324 (2005). (Pubitemid 46218724)
75. Ward RL, Cheong K, Ku SL, Meagher A, OConnor T, Hawkins NJ: Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J. Clin. Oncol. 21(20), 3729-3736 (2003). (Pubitemid 46606226)
76. Saunders M, Iveson T: Management of advanced colorectal cancer: state of the art. Br. J. Cancer 95(2), 131-138 (2006). (Pubitemid 44050911)
77. Nelson H, Petrelli N, Carlin A et al.: Guidelines 2000 for colon and rectal cancer surgery. J. Natl Cancer Inst. 93(8), 583-596 (2001). (Pubitemid 32409626)
78. Loupakis F, Masi G, Vasile E, Falcone A: First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first? Curr. Opin. Oncol. 20(4), 459-465 (2008).
79. Taieb J, Puig PL, Bedenne L: Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial. Expert Rev. Anticancer Ther. 8(2), 183-189 (2008). (Pubitemid 351385908)
80. Wolpin BM, Mayer RJ: Systemic treatment of colorectal cancer. Gastroenterology 134(5), 1296-1310 (2008).
81. Moertel CG, Fleming TR, Macdonald JS et al.: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 322(6), 352-358 (1990). (Pubitemid 20042739)
82. Tabernero J, van Cutsem E, Diaz-Rubio E et al.: Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 25(33), 5225-5232 (2007). (Pubitemid 350232254)
83. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S: Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J. Clin. Oncol. 23(16), 3706-3712 (2005). (Pubitemid 46252465)
84. Moroni M, Veronese S, Benvenuti S et al.: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 6(5), 279-286 (2005). (Pubitemid 40590264)
85. Lievre A, Bachet JB, Le Corre D et al.: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66(8), 3992-3995 (2006).
86. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al.: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 67(6), 2643-2648 (2007). (Pubitemid 46548951)
87. Khambata-Ford S, Garrett CR, Meropol NJ et al.: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25(22), 3230-3237 (2007). (Pubitemid 47325606)
88. Di Fiore F, Blanchard F, Charbonnier F et al.: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br. J. Cancer 96(8), 1166-1169 (2007). (Pubitemid 46625066)
89. Iacopetta B, Grieu F, Joseph D, Elsaleh H: A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br. J. Cancer 85(6), 827-830 (2001). (Pubitemid 33010548)
90. Villafranca E, Okruzhnov Y, Dominguez MA et al.: Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J. Clin. Oncol. 19(6), 1779-1786 (2001). (Pubitemid 32230880)
91. Marsh S: Thymidylate synthase pharmacogenetics. Invest. New Drugs 23(6), 533-537 (2005). (Pubitemid 43162472)
92. Pullarkat ST, Stoehlmacher J, Ghaderi V et al.: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1(1), 65-70 (2001).
93. Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J: Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J. Clin. Oncol. 23(7), 1365-1369 (2005). (Pubitemid 46260023)
94. Bandres E, Zarate R, Ramirez N, Abajo A, Bitarte N, Gariia-Foncillas J: Pharmacogenomics in colorectal cancer: the first step for individualized- therapy. World J. Gastroenterol. 13(44), 5888-5901 (2007). (Pubitemid 350148505)
95. Ribic CM, Sargent DJ, Moore MJ et al.: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349(3), 247-257 (2003).
96. Elsaleh H, Powell B, Soontrapornchai P et al.: p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes C colon carcinoma. Oncology 58(1), 52-59 (2000). (Pubitemid 30045310)
97. Funke S, Brenner H, Chang-Claude J: Pharmacogenetics in colorectal cancer: a systematic review. Pharmacogenomics 9(8), 1079-1099 (2008).
98. Esteller M, Herman JG: Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene 23(1), 1-8 (2004). (Pubitemid 38142234)
99. Laird PW: The power and the promise of DNA methylation markers. Nat. Rev. Cancer 3(4), 253-266 (2003).
100. Shen L, Catalano PJ, Benson AB 3rd, ODwyer P, Hamilton SR, Issa JP: Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin. Cancer Res. 13(20), 6093-6098 (2007). (Pubitemid 350075067)
101. Konishi K, Issa JP: Targeting aberrant chromatin structure in colorectal carcinomas. Cancer J. 13(1), 49-55 (2007).
102. Ropero S, Fraga MF, Ballestar E et al.: A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat. Genet. 38(5), 566-569 (2006).
103. Marks PA, Jiang X: Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 4(4), 549-551 (2005). (Pubitemid 41359778)
104. Ree AH, Folkvord S, Flatmark K: HDAC2 deficiency and histone acetylation. Nat. Genet. 40(7), 812-813; author reply 813 (2008). (Pubitemid 351913664)
105. Hanigan CL, van Engeland M, de Brune AP et al.: An inactivating mutation in HDAC2 leads to a dysregulation of apoptosis mediated by APAF1. Gastroenterology 135(5), 1654-1664 (2008).
106. Lyall MS, Dundas SR, Curran S, Murray GI: Profiling markers of prognosis in colorectal cancer. Clin. Cancer Res. 12(4), 1184-1191 (2006). (Pubitemid 43342507)
107. Agrelo R, Cheng WH, Setien F et al.: Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc. Natl Acad. Sci. USA 103(23), 8822-8827 (2006). (Pubitemid 43878103)
108. Kawasaki T, Ohnishi M, Suemoto Y et al.: WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod. Pathol. 21(2), 150-158 (2008). (Pubitemid 351172166)
109. Scolnick DM, Halazonetis TD: Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature 406(6794), 430-435 (2000).
110. Toyota M, Sasaki Y, Satoh A et al.: Epigenetic inactivation of CHFR in human tumors. Proc. Natl Acad. Sci. USA 100(13), 7818-7823 (2003). (Pubitemid 36760053)
111. Tokunaga E, Oki E, Nishida K et al.: Aberrant hypermethylation of the promoter region of the CHFR gene is rare in primary breast cancer. Breast Cancer Res. Treat. 97(2), 199-203 (2006).
112. Yanokura M, Banno K, Kawaguchi M et al.: Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer. Oncol. Rep. 17(1), 41-48 (2007).
113. Banno K, Yanokura M, Kawaguchi M et al.: Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. Int. J. Oncol. 31(4), 713-720 (2007).
114. Yoshida K, Hamai Y, Suzuki T, Sanada Y, Oue N, Yasui W: DNA methylation of CHFR is not a predictor of the response to docetaxel and paclitaxel in advanced and recurrent gastric cancer. Anticancer Res. 26(1A), 49-54 (2006). (Pubitemid 43206059)
115. Satoh A, Toyota M, Itoh F et al.: Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res. 63(24), 8606-8613 (2003). (Pubitemid 38064034)
116. Swanton C, Tomlinson I, Downward J: Chromosomal instability, colorectal cancer and taxane resistance. Cell Cycle 5(8), 818-823 (2006). (Pubitemid 44145573)
117. Corn PG, Summers MK, Fogt F et al.: Frequent hypermethylation of the 5′ CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis 24(1), 47-51 (2003). (Pubitemid 36193194)
118. Brandes JC, van Engeland M, Wouters KA, Weijenberg MP, Herman JG: CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype. Carcinogenesis 26(6), 1152-1156 (2005). (Pubitemid 41214309)
119. Clark SJ, Harrison J, Paul CL, Frommer M: High sensitivity mapping of methylated cytosines. Nucleic Acids Res. 22(15), 2990-2997 (1994). (Pubitemid 24260626)
120. Bernstein BE, Meissner A, Lander ES: The mammalian epigenome. Cell 128(4), 669-681 (2007). (Pubitemid 46273573)
121. Down TA, Rakyan VK, Turner DJ et al.: A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis. Nat. Biotechnol. 26(7), 779-785 (2008).
122. Suzuki H, Gabrielson E, Chen W et al.: A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet. 31(2), 141-149 (2002).
123. Chung W, Kwabi-Addo B, Ittmann M, Jelinek J, Shen L, Yu Y, Issa JP: Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS ONE 3(4), E2079 (2008). (Pubitemid 352025019)
124. Wilson IM, Davies JJ, Weber M et al.: Epigenomics: mapping the methylome. Cell Cycle 5(2), 155-158 (2006). (Pubitemid 43131150)
125. Beck S, Rakyan VK: The methylome: approaches for global DNA methylation profiling. Trends Genet. 24(5), 231-237 (2008).
126. Rauch T, Li H, Wu X, Pfeifer GP: MIRAassisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain-containing genes in lung Cancer Cells. Cancer Res. 66(16), 7939-7947 (2006). (Pubitemid 44299157)
127. Feltus FA, Lee EK, Costello JF, Plass C, Vertino PM: Predicting aberrant CpG island methylation. Proc. Natl Acad. Sci. USA 100(21), 12253-12258 (2003). (Pubitemid 37271547)
128. Yamashita K, Upadhyay S, Osada M et al.: Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2(6), 485-495 (2002). (Pubitemid 41043953)
129. Barski A, Cuddapah S, Cui K et al.: High-resolution profiling of histone methylations in the human genome. Cell 129(4), 823-837 (2007). (Pubitemid 46802390)
130. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl Cancer Inst. 97(16), 1180-1184 (2005). (Pubitemid 41258223)
131. Ioannidis JP: Is molecular profiling ready for use in clinical decision making? Oncologist 12(3), 301-311 (2007).
132. Ioannidis JP: Why most published research findings are false. PLoS Med. 2(8), E124 (2005).
133. Ioannidis JP: Molecular bias. Eur. J. Epidemiol. 20(9), 739-745 (2005).
134. Partridge M, Gaballah K, Huang X: Molecular markers for diagnosis and prognosis. Cancer Metastasis Rev. 24(1), 71-85 (2005). (Pubitemid 40576064)